Is Reddit a Buy on the Dip?
Reddit (NYSE:RDDT) share price has been on the proverbial ropes…
Sell
46
LUCD Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
-22.4%
Day range:
$1.29 - $1.46
52-week range:
$0.63 - $1.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.43x
P/B ratio:
--
Volume:
1.2M
Avg. volume:
824.7K
1-year change:
24.11%
Market cap:
$82.5M
Revenue:
$2.4M
EPS (TTM):
-$1.13
Analysts' Opinion
-
Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.50, Lucid Diagnostics has an estimated upside of 151.8% from its current price of $1.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.39.
Fair Value
-
According to the consensus of 4 analysts, Lucid Diagnostics has 151.8% upside to fair value with a price target of $3.50 per share.
LUCD vs. S&P 500
-
Over the past 5 trading days, Lucid Diagnostics has overperformed the S&P 500 by 2.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Lucid Diagnostics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lucid Diagnostics has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Lucid Diagnostics reported revenues of $1.2M.
Earnings Growth
-
Lucid Diagnostics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lucid Diagnostics reported earnings per share of -$0.25.
Enterprise value:
134.1M
EV / Invested capital:
--
Price / LTM sales:
15.43x
EV / EBIT:
--
EV / Revenue:
32.02x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$2.2M
Return On Assets:
-150.12%
Net Income Margin (TTM):
-1069.9%
Return On Equity:
-650.37%
Return On Invested Capital:
-229.99%
Operating Margin:
-997.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $1.5M | $4.2M | $783K | $1.2M | |
| Gross Profit | -$1.9M | -$4.6M | -$2.2M | -$851K | -$512K | |
| Operating Income | -$52.5M | -$52M | -$45.1M | -$11.1M | -$11.7M | |
| EBITDA | -$51.2M | -$53.9M | -$43.2M | -$13.4M | -$12.2M | |
| Diluted EPS | -$1.47 | -$1.41 | -$1.13 | -$0.34 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $2.5M | $29.8M | $27.3M | $16.8M | |
| Total Assets | -- | $3.3M | $38.4M | $33.2M | $22.6M | |
| Current Liabilities | -- | $27.4M | $9.7M | $30.2M | $14.2M | |
| Total Liabilities | -- | $27.4M | $10.8M | $30.7M | $16.3M | |
| Total Equity | -- | -$24.1M | $27.5M | $2.6M | $6.3M | |
| Total Debt | -- | -- | -- | $14.5M | $10.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.3M | -$27.1M | -$44.2M | -$8.8M | -$10.2M | |
| Cash From Investing | -$4.7M | -$249K | -$562K | -$14K | -$350K | |
| Cash From Financing | $66.9M | $24.5M | $35.2M | $275K | $94K | |
| Free Cash Flow | -$36.8M | -$27.3M | -$44.8M | -$8.8M | -$10.5M | |
LUCD
Sector
Market Cap
$82.5M
$38.4M
Price % of 52-Week High
85.12%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
0.67%
-0.78%
1-Year Price Total Return
24.11%
-39.05%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.33
200-day SMA
Buy
Level
$0.91
Bollinger Bands (100)
Buy
Level
0.77 - 1.23
Chaikin Money Flow
Buy
Level
5.6M
20-day SMA
Sell
Level
$1.40
Relative Strength Index (RSI14)
Buy
Level
56.55
ADX Line
Buy
Level
27.62
Williams %R
Neutral
Level
-43.2432
50-day SMA
Buy
Level
$1.10
MACD (12, 26)
Buy
Level
0.06
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.7059)
Sell
CA Score
(Annual)
Level (-9.0175)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (13.4633)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Stock Forecast FAQ
In the current month, LUCD has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LUCD average analyst price target in the past 3 months is $3.50.
-
Where Will Lucid Diagnostics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lucid Diagnostics share price will rise to $3.50 per share over the next 12 months.
-
What Do Analysts Say About Lucid Diagnostics?
Analysts are divided on their view about Lucid Diagnostics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lucid Diagnostics is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Lucid Diagnostics's Price Target?
The price target for Lucid Diagnostics over the next 1-year time period is forecast to be $3.50 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LUCD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lucid Diagnostics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LUCD?
You can purchase shares of Lucid Diagnostics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lucid Diagnostics shares.
-
What Is The Lucid Diagnostics Share Price Today?
Lucid Diagnostics was last trading at $1.40 per share. This represents the most recent stock quote for Lucid Diagnostics. Yesterday, Lucid Diagnostics closed at $1.39 per share.
-
How To Buy Lucid Diagnostics Stock Online?
In order to purchase Lucid Diagnostics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Qualcomm Stock: 5G Leader at a Bargain Price?
Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…
What Is Buffett Buying and Selling Now?
In Q4 of last year, Warren Buffett made a few…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 15
Gorilla Technology Group [GRRR] is up 29.72% over the past day.
Sell
49
SMTC alert for Mar 15
Semtech [SMTC] is up 21.28% over the past day.
Buy
62
PLPC alert for Mar 15
Preformed Line Products [PLPC] is up 17.38% over the past day.
